vs
Amphastar Pharmaceuticals, Inc.（AMPH）とPROGRESS SOFTWARE CORP（PRGS）の財務データ比較。上の社名をクリックして会社を切り替えられます
PROGRESS SOFTWARE CORPの直近四半期売上が大きい（$252.7M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.4倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 10.2%、差は3.2%）。PROGRESS SOFTWARE CORPの前年同期比売上増加率が高い（17.5% vs -1.8%）。PROGRESS SOFTWARE CORPの直近四半期フリーキャッシュフローが多い（$59.9M vs $24.6M）。過去8四半期でPROGRESS SOFTWARE CORPの売上複合成長率が高い（17.0% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
プログレスソフトウェアコーポレーションは、アプリケーション開発プラットフォーム、データ接続ツール、デジタルエクスペリエンスソリューションなどの企業向けソフトウェアを開発・販売しています。金融、医療、製造、小売など世界中の多様な業界の顧客にサービスを提供し、業務効率化と高性能業務アプリの構築を支援しています。
AMPH vs PRGS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $252.7M |
| 純利益 | $24.4M | $25.7M |
| 粗利率 | 46.8% | 81.6% |
| 営業利益率 | 19.4% | 15.2% |
| 純利益率 | 13.3% | 10.2% |
| 売上前年比 | -1.8% | 17.5% |
| 純利益前年比 | -35.7% | 2144.6% |
| EPS（希薄化後） | $0.51 | $0.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $252.7M | ||
| Q3 25 | $191.8M | $249.8M | ||
| Q2 25 | $174.4M | $237.4M | ||
| Q1 25 | $170.5M | $238.0M | ||
| Q4 24 | $186.5M | $215.0M | ||
| Q3 24 | $191.2M | $178.7M | ||
| Q2 24 | $182.4M | $175.1M | ||
| Q1 24 | $171.8M | $184.7M |
| Q4 25 | $24.4M | $25.7M | ||
| Q3 25 | $17.4M | $19.4M | ||
| Q2 25 | $31.0M | $17.0M | ||
| Q1 25 | $25.3M | $10.9M | ||
| Q4 24 | $38.0M | $1.1M | ||
| Q3 24 | $40.4M | $28.5M | ||
| Q2 24 | $37.9M | $16.2M | ||
| Q1 24 | $43.2M | $22.6M |
| Q4 25 | 46.8% | 81.6% | ||
| Q3 25 | 51.4% | 81.0% | ||
| Q2 25 | 49.6% | 80.1% | ||
| Q1 25 | 50.0% | 80.6% | ||
| Q4 24 | 46.5% | 83.0% | ||
| Q3 24 | 53.3% | 83.7% | ||
| Q2 24 | 52.2% | 81.7% | ||
| Q1 24 | 52.4% | 82.2% |
| Q4 25 | 19.4% | 15.2% | ||
| Q3 25 | 13.2% | 17.6% | ||
| Q2 25 | 24.2% | 16.3% | ||
| Q1 25 | 21.9% | 13.6% | ||
| Q4 24 | 24.2% | 10.0% | ||
| Q3 24 | 29.8% | 22.6% | ||
| Q2 24 | 30.3% | 15.5% | ||
| Q1 24 | 27.9% | 19.0% |
| Q4 25 | 13.3% | 10.2% | ||
| Q3 25 | 9.0% | 7.8% | ||
| Q2 25 | 17.8% | 7.2% | ||
| Q1 25 | 14.8% | 4.6% | ||
| Q4 24 | 20.4% | 0.5% | ||
| Q3 24 | 21.1% | 15.9% | ||
| Q2 24 | 20.8% | 9.2% | ||
| Q1 24 | 25.1% | 12.3% |
| Q4 25 | $0.51 | $0.59 | ||
| Q3 25 | $0.37 | $0.44 | ||
| Q2 25 | $0.64 | $0.39 | ||
| Q1 25 | $0.51 | $0.24 | ||
| Q4 24 | $0.74 | $0.01 | ||
| Q3 24 | $0.78 | $0.65 | ||
| Q2 24 | $0.73 | $0.37 | ||
| Q1 24 | $0.81 | $0.51 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $94.8M |
| 総負債低いほど良い | $608.7M | $1.4B |
| 株主資本純資産 | $788.8M | $478.3M |
| 総資産 | $1.6B | $2.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 2.93× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $94.8M | ||
| Q3 25 | $276.2M | $99.0M | ||
| Q2 25 | $231.8M | $102.0M | ||
| Q1 25 | $236.9M | $124.2M | ||
| Q4 24 | $221.6M | $118.1M | ||
| Q3 24 | $250.5M | $232.7M | ||
| Q2 24 | $217.8M | $190.4M | ||
| Q1 24 | $289.6M | $133.2M |
| Q4 25 | $608.7M | $1.4B | ||
| Q3 25 | $608.6M | $1.4B | ||
| Q2 25 | $607.7M | $1.5B | ||
| Q1 25 | $603.9M | $1.5B | ||
| Q4 24 | $601.6M | $1.5B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $478.3M | ||
| Q3 25 | $776.7M | $477.7M | ||
| Q2 25 | $757.5M | $452.7M | ||
| Q1 25 | $751.3M | $431.8M | ||
| Q4 24 | $732.3M | $438.8M | ||
| Q3 24 | $727.7M | $425.6M | ||
| Q2 24 | $713.3M | $401.7M | ||
| Q1 24 | $672.4M | $461.7M |
| Q4 25 | $1.6B | $2.5B | ||
| Q3 25 | $1.7B | $2.4B | ||
| Q2 25 | $1.6B | $2.4B | ||
| Q1 25 | $1.6B | $2.5B | ||
| Q4 24 | $1.6B | $2.5B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.6B | $1.5B |
| Q4 25 | 0.77× | 2.93× | ||
| Q3 25 | 0.78× | 2.97× | ||
| Q2 25 | 0.80× | 3.22× | ||
| Q1 25 | 0.80× | 3.50× | ||
| Q4 24 | 0.82× | 3.48× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $62.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $59.9M |
| FCFマージンFCF / 売上 | 13.4% | 23.7% |
| 設備投資強度設備投資 / 売上 | 4.5% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 2.44× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $229.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $62.8M | ||
| Q3 25 | $52.6M | $73.4M | ||
| Q2 25 | $35.6M | $30.0M | ||
| Q1 25 | $35.1M | $68.9M | ||
| Q4 24 | $29.0M | $19.7M | ||
| Q3 24 | $60.0M | $57.7M | ||
| Q2 24 | $69.1M | $63.7M | ||
| Q1 24 | $55.3M | $70.5M |
| Q4 25 | $24.6M | $59.9M | ||
| Q3 25 | $47.2M | $72.4M | ||
| Q2 25 | $25.0M | $29.5M | ||
| Q1 25 | $24.4M | $67.7M | ||
| Q4 24 | $16.6M | $16.8M | ||
| Q3 24 | $46.2M | $56.6M | ||
| Q2 24 | $63.1M | $62.7M | ||
| Q1 24 | $46.5M | $70.2M |
| Q4 25 | 13.4% | 23.7% | ||
| Q3 25 | 24.6% | 29.0% | ||
| Q2 25 | 14.3% | 12.4% | ||
| Q1 25 | 14.3% | 28.4% | ||
| Q4 24 | 8.9% | 7.8% | ||
| Q3 24 | 24.1% | 31.7% | ||
| Q2 24 | 34.6% | 35.8% | ||
| Q1 24 | 27.1% | 38.0% |
| Q4 25 | 4.5% | 1.1% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.5% | ||
| Q4 24 | 6.7% | 1.3% | ||
| Q3 24 | 7.2% | 0.6% | ||
| Q2 24 | 3.3% | 0.5% | ||
| Q1 24 | 5.1% | 0.2% |
| Q4 25 | 1.35× | 2.44× | ||
| Q3 25 | 3.03× | 3.78× | ||
| Q2 25 | 1.15× | 1.76× | ||
| Q1 25 | 1.39× | 6.30× | ||
| Q4 24 | 0.76× | 17.13× | ||
| Q3 24 | 1.48× | 2.03× | ||
| Q2 24 | 1.82× | 3.93× | ||
| Q1 24 | 1.28× | 3.11× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
